Atrial flutter medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
The management of atrial flutter is similar to that of [[atrial fibrillation]] with primary goals being control of ventricular rate, restoration of sinus rhythm, and prevention of recurrent episodes and thromboembolic episodes. In the setting of unstable hemodynamics immediate electrical [[cardioversion]] is recommended.  because of the high success rate and low complication rate [[radiofrequency ablation]] is considered superior to medical therapy in atrial flutter.
The management of atrial flutter is similar to that of [[atrial fibrillation]] with primary goals being control of ventricular rate, restoration of [[sinus rhythm]], and prevention of recurrent episodes and [[Thromboembolic disease|thromboembolic]] episodes. In the setting of unstable hemodynamics immediate electrical [[cardioversion]] is recommended.  because of the high success rate and low complication rate [[radiofrequency ablation]] is considered superior to medical therapy in atrial flutter.


==Medical Therapy==
==Medical Therapy==
Treatment goals in the management of atrial flutter include:
Treatment goals in the management of atrial flutter include:
* Control of ventricular rate
* Control of ventricular rate
* Reversion to normal sinus rhythm (NSR)
* Reversion to [[normal sinus rhythm]] (NSR)
* Prevention of recurrent episodes and prevention of complications
* Prevention of recurrent episodes and prevention of [[systemic embolization]]


Treatment modalities for atrial flutter include:  
Treatment modalities for atrial flutter include:  
====Electric Cardioversion====
====Electric Cardioversion====
Synchronous direct current (DC) [[cardioversion]] is used as the initial treatment strategy in the management of [[hemodynamically unstable]] atrial flutter patients in emergency department.  External electrical [[cardioversion]] is effective in more than 90% of the cases and the initial shock strength used is 50 joules biphasic direct current.  Sometimes the first shock may convert an atrial flutter to atrial fibrillation, in such cases a second shock preferable of a higher strength is usually given to restore sinus rhythm.  Electric [[cardioversion]] increases the risk of [[stroke]] and hence pre-treatment with a blood thinner is advised if time permits.
Synchronous direct current (DC) [[cardioversion]] is used as the initial treatment strategy in the management of [[hemodynamically unstable]] atrial flutter patients in emergency department.  External electrical [[cardioversion]] is effective in more than 90% of the cases and the initial shock strength used is 50 joules biphasic direct current.  Sometimes the first shock may convert an atrial flutter to atrial fibrillation, in such cases a second shock preferable of a higher strength is usually given to restore [[sinus rhythm]].  Electric [[cardioversion]] increases the risk of [[stroke]] and hence pre-treatment with a blood thinner is advised if time permits.


====AV Nodal Agents====
====AV Nodal Agents====
Ventricular rate control is the prime goal in the management of atrial flutter.  Drugs such as [[Calcium channel blocker|calcium channel blockers]] ([[verapamil]] or [[diltiazem]]) or [[beta-blocker]]s can be used for this.  These drugs act as AV node blocking agents and control ventricular rate, thereby preventing [[tachycardia induced cardiomyopathy]].  Beta-blockers also have a direct [[Antiarrhythmic agent|antiarrhythmic]] effect on the atria. Administration of [[adenosine]] reveals flutter waves by blocking the AV node.  History of [[Wolff-Parkinson-White syndrome]] or [[pre-excitation syndrome]] has to be ruled out before administrating, as these agents while acting on AV node can accelerate conduction in the accessory pathways and can precipitate [[ventricular fibrillation]]. [[Digoxin]] can also be used as an AV blocking agent in combination with [[calcium channel blockers]] and [[beta-blockers]] in the event of failure of electric [[cardioversion]], atrial pacing and pharmacologic therapy.
Ventricular rate control is the prime goal in the management of atrial flutter.  Drugs such as [[Calcium channel blocker|calcium channel blockers]] ([[verapamil]] or [[diltiazem]]) or [[beta-blocker]]s can be used for this.  These drugs act as AV node blocking agents and control ventricular rate, thereby preventing [[tachycardia induced cardiomyopathy]].  Beta-blockers also have a direct [[Antiarrhythmic agent|antiarrhythmic]] effect on the atria. Administration of [[adenosine]] reveals flutter waves by blocking the [[AV node]].  History of [[Wolff-Parkinson-White syndrome]] or [[pre-excitation syndrome]] has to be ruled out before administrating, as these agents while acting on AV node can accelerate conduction in the accessory pathways and can precipitate [[ventricular fibrillation]]. [[Digoxin]] can also be used as an AV blocking agent in combination with [[calcium channel blockers]] and [[beta-blockers]] in the event of failure of electric [[cardioversion]], atrial pacing and pharmacologic therapy.


====Antiarrhythmic Agents====
====Antiarrhythmic Agents====
Class III agents like [[ibutilide]], [[dofetilide]], [[sotalol]] or [[amiodarone]] are typically used for pharmacologic [[cardioversion]] in the treatment of atrial flutter.  Intravenous ibutilide is very effective in controlling acute atrial flutter episode and is found to be effective in at least 63% patients.  Patients who are administered i.v ibutilide should be monitored using an EKG for at least 4 hrs after the infusion as [[ibutilide]] is known to cause [[QT prolongation]] and [[torsades de pointes]].
Class III agents like [[ibutilide]], [[dofetilide]], [[sotalol]] or [[amiodarone]] are typically used for pharmacologic [[cardioversion]] in the treatment of atrial flutter.  Intravenous ibutilide is very effective in controlling acute atrial flutter episode and is found to be effective in at least 63% patients.  Patients who are administered i.v ibutilide should be monitored using an EKG for at least 4 hrs after the infusion as [[ibutilide]] is known to cause [[QT prolongation]] and [[torsades de pointes]].


Class IC agents like [[propafenone]] or [[flecainide]] have also shown to be effective in the conversion of acute onset atrial flutter to normal sinus rhythm.
Class IC agents like [[propafenone]] or [[flecainide]] have also shown to be effective in the conversion of acute onset atrial flutter to [[normal sinus rhythm]].


====Rapid Atrial Pacing====
====Rapid Atrial Pacing====

Revision as of 16:12, 6 January 2020

Atrial flutter Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atrial flutter from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

EKG Examples

Chest X Ray

Echocardiography

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

2015 ACC/AHA Guideline Recommendations

Acute Treatment of Atrial Flutter
Ongoing Management of Atrial Flutter

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Atrial flutter medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atrial flutter medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atrial flutter medical therapy

CDC on Atrial flutter medical therapy

Atrial flutter medical therapy in the news

Blogs on Atrial flutter medical therapy

Directions to Hospitals Treating Atrial flutter

Risk calculators and risk factors for Atrial flutter medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Overview

The management of atrial flutter is similar to that of atrial fibrillation with primary goals being control of ventricular rate, restoration of sinus rhythm, and prevention of recurrent episodes and thromboembolic episodes. In the setting of unstable hemodynamics immediate electrical cardioversion is recommended. because of the high success rate and low complication rate radiofrequency ablation is considered superior to medical therapy in atrial flutter.

Medical Therapy

Treatment goals in the management of atrial flutter include:

Treatment modalities for atrial flutter include:

Electric Cardioversion

Synchronous direct current (DC) cardioversion is used as the initial treatment strategy in the management of hemodynamically unstable atrial flutter patients in emergency department. External electrical cardioversion is effective in more than 90% of the cases and the initial shock strength used is 50 joules biphasic direct current. Sometimes the first shock may convert an atrial flutter to atrial fibrillation, in such cases a second shock preferable of a higher strength is usually given to restore sinus rhythm. Electric cardioversion increases the risk of stroke and hence pre-treatment with a blood thinner is advised if time permits.

AV Nodal Agents

Ventricular rate control is the prime goal in the management of atrial flutter. Drugs such as calcium channel blockers (verapamil or diltiazem) or beta-blockers can be used for this. These drugs act as AV node blocking agents and control ventricular rate, thereby preventing tachycardia induced cardiomyopathy. Beta-blockers also have a direct antiarrhythmic effect on the atria. Administration of adenosine reveals flutter waves by blocking the AV node. History of Wolff-Parkinson-White syndrome or pre-excitation syndrome has to be ruled out before administrating, as these agents while acting on AV node can accelerate conduction in the accessory pathways and can precipitate ventricular fibrillation. Digoxin can also be used as an AV blocking agent in combination with calcium channel blockers and beta-blockers in the event of failure of electric cardioversion, atrial pacing and pharmacologic therapy.

Antiarrhythmic Agents

Class III agents like ibutilide, dofetilide, sotalol or amiodarone are typically used for pharmacologic cardioversion in the treatment of atrial flutter. Intravenous ibutilide is very effective in controlling acute atrial flutter episode and is found to be effective in at least 63% patients. Patients who are administered i.v ibutilide should be monitored using an EKG for at least 4 hrs after the infusion as ibutilide is known to cause QT prolongation and torsades de pointes.

Class IC agents like propafenone or flecainide have also shown to be effective in the conversion of acute onset atrial flutter to normal sinus rhythm.

Rapid Atrial Pacing

As external electrical cardioversion requires anesthesia some doctors prefer atrial overdrive pacing to terminate episodes of atrial flutter. In overdrive pacing the atria are continuously paced at a rate higher than that of the patient's sinus node, which causes an alteration in the atrial rate, propagation and also suppresses the automaticity caused by electrical remodeling in the diseased fibers. Unsuccessful pacing can be due to:[1]

  • Insufficient rate and duration of pacing
  • Bad electrode contact in the atrium
  • Insufficient outlet current

Contraindicated medications

Atrial flutter is considered an absolute contraindication to the use of the following medications:

References

  1. Rozsíval V, Kvasnicka J (1984). "Atrial flutter treatment by rapid atrial pacing". Cor Vasa. 26 (3): 167–72. PMID 6478843.

Template:WH Template:WS